225 related articles for article (PubMed ID: 35109866)
21. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
Nakanishi K; Nakamura S; Sugiyama T; Kadomatsu Y; Ueno H; Goto M; Ozeki N; Fukui T; Iwano S; Chen-Yoshikawa TF
BMC Cancer; 2021 Sep; 21(1):983. PubMed ID: 34474680
[TBL] [Abstract][Full Text] [Related]
23. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
Huang YS; Chen JL; Chen JY; Lee YF; Huang JY; Kuo SH; Yen RF; Chang YC
Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
[TBL] [Abstract][Full Text] [Related]
24. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
25. Tumor response evaluation by combined modalities of chest magnetic resonance imaging and computed tomography in locally advanced non-small cell lung cancer after concurrent chemoradiotherapy.
Wang D; Qiu B; He H; Yin S; Peng K; Hu N; Guo J; Li Q; Chen N; Chu C; Liu F; Xie CM; Liu H
Radiother Oncol; 2022 Mar; 168():211-220. PubMed ID: 35131342
[TBL] [Abstract][Full Text] [Related]
26. PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort.
Brose A; Michalski K; Ruf J; Tosch M; Eschmann SM; Schreckenberger M; König J; Nestle U; Miederer M
Cancer Imaging; 2023 May; 23(1):45. PubMed ID: 37198668
[TBL] [Abstract][Full Text] [Related]
27. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer.
Pöttgen C; Gauler T; Bellendorf A; Guberina M; Bockisch A; Schwenzer N; Heinzelmann F; Cordes S; Schuler MH; Welter S; Stamatis G; Friedel G; Darwiche K; Jöckel KH; Eberhardt W; Stuschke M
J Clin Oncol; 2016 Jul; 34(21):2526-33. PubMed ID: 27247220
[TBL] [Abstract][Full Text] [Related]
28. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
30. To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [
Li L; Wei Y; Huang Y; Yu Q; Liu W; Zhao S; Zheng J; Lu H; Yu J; Yuan S
Mol Imaging Biol; 2018 Dec; 20(6):1061-1067. PubMed ID: 29623510
[TBL] [Abstract][Full Text] [Related]
31. Planned FDG PET-CT Scan in Follow-Up Detects Disease Progression in Patients With Locally Advanced NSCLC Receiving Curative Chemoradiotherapy Earlier Than Standard CT.
Pan Y; Brink C; Schytte T; Petersen H; Wu YL; Hansen O
Medicine (Baltimore); 2015 Oct; 94(43):e1863. PubMed ID: 26512597
[TBL] [Abstract][Full Text] [Related]
32.
Lee S; Choi Y; Park G; Jo S; Lee SS; Park J; Shim HK
Technol Cancer Res Treat; 2021; 20():15330338211024655. PubMed ID: 34227434
[TBL] [Abstract][Full Text] [Related]
33. Clinical Effects of PET-CT Before Definite Concurrent Chemoradiotherapy in Patients With Unresectable Stage IIIA-IIIB Squamous Cell Carcinoma of the Lungs.
Lin WC; Chen WM; Chen M; Shia BC; Wu SY
Clin Nucl Med; 2022 Aug; 47(8):677-683. PubMed ID: 35695702
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer.
Oh D; Lee JE; Huh SJ; Park W; Nam H; Choi JY; Kim BT
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):549-54. PubMed ID: 24074928
[TBL] [Abstract][Full Text] [Related]
35. The Role of 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography/Computed Tomography as Response and Prognosis Predictive Factor of Concurrent Chemoradiotherapy after Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Study.
Šedienė S; Kulakienė I; Rudžianskas V; Ambrazienė R
Medicina (Kaunas); 2018 May; 54(2):. PubMed ID: 30344262
[No Abstract] [Full Text] [Related]
36. Local and regional treatment response by
van Diessen JNA; La Fontaine M; van den Heuvel MM; van Werkhoven E; Walraven I; Vogel WV; Belderbos JSA; Sonke JJ
Radiother Oncol; 2020 Feb; 143():30-36. PubMed ID: 31767474
[TBL] [Abstract][Full Text] [Related]
37. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy.
Yan H; Wang R; Zhao F; Zhu K; Jiang S; Zhao W; Feng R
Acta Radiol; 2011 Jul; 52(6):646-50. PubMed ID: 21508201
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer.
Saga T; Inubushi M; Koizumi M; Yoshikawa K; Zhang MR; Tanimoto K; Horiike A; Yanagitani N; Ohyanagi F; Nishio M
Cancer Sci; 2015 Nov; 106(11):1554-60. PubMed ID: 26292100
[TBL] [Abstract][Full Text] [Related]
39. Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer.
Zhang N; Liang R; Gensheimer MF; Guo M; Zhu H; Yu J; Diehn M; Loo BW; Li R; Wu J
Theranostics; 2020; 10(25):11707-11718. PubMed ID: 33052242
[TBL] [Abstract][Full Text] [Related]
40. The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer.
Kim KR; Shim HJ; Hwang JE; Cho SH; Chung IJ; Park KS; Kang SR; Kwon SY; Chung WK; Bae WK
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):170-178. PubMed ID: 28940101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
